MRKR - Marker Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
126.31M
Enterprise Value 3
81.45M
Trailing P/E
N/A
Forward P/E 1
-5.30
PEG Ratio (5 yr expected) 1
N/A
Price/Sales (ttm)
Price/Book (mrq)
2.73
Enterprise Value/Revenue 3
N/A
Enterprise Value/EBITDA 6
N/A

Trading Information

Stock Price History

Beta (3Y Monthly) 0.13
52-Week Change 3-60.97%
S&P500 52-Week Change 313.17%
52 Week High 39.1700
52 Week Low 32.6973
50-Day Moving Average 34.2625
200-Day Moving Average 35.5377

Share Statistics

Avg Vol (3 month) 3301.07k
Avg Vol (10 day) 3528.31k
Shares Outstanding 545.72M
Float 25.78M
% Held by Insiders 131.87%
% Held by Institutions 143.37%
Shares Short (Oct 31, 2019) 45.09M
Short Ratio (Oct 31, 2019) 423.19
Short % of Float (Oct 31, 2019) 417.83%
Short % of Shares Outstanding (Oct 31, 2019) 411.14%
Shares Short (prior month Sep 30, 2019) 44.29M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 212/1
Last Split Date 3Sep 16, 2016

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Sep 30, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-333.91%
Return on Equity (ttm)-625.50%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)0.00
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)205.99k
EBITDA N/A
Net Income Avi to Common (ttm)-151.91M
Diluted EPS (ttm)-3.4380
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)48.48M
Total Cash Per Share (mrq)1.06
Total Debt (mrq)532.75k
Total Debt/Equity (mrq)1.11
Current Ratio (mrq)15.83
Book Value Per Share (mrq)1.05

Cash Flow Statement

Operating Cash Flow (ttm)-19.89M
Levered Free Cash Flow (ttm)-77.57M